HOLX * Stock Overview
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,207.71 |
| 52 Week High | US$1,265.13 |
| 52 Week Low | US$1,207.71 |
| Beta | 1.02 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -21.17% |
| 5 Year Change | 31.85% |
| Change since IPO | 36.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOLX * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how HOLX * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how HOLX * performed against the MX Market.
Price Volatility
| HOLX * volatility | |
|---|---|
| HOLX * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: HOLX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HOLX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HOLX * fundamental statistics | |
|---|---|
| Market cap | Mex$294.22b |
| Earnings (TTM) | Mex$8.77b |
| Revenue (TTM) | Mex$67.55b |
33.6x
P/E Ratio4.4x
P/S RatioIs HOLX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOLX * income statement (TTM) | |
|---|---|
| Revenue | US$3.97b |
| Cost of Revenue | US$1.55b |
| Gross Profit | US$2.42b |
| Other Expenses | US$1.91b |
| Earnings | US$515.10m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.19 |
| Gross Margin | 60.99% |
| Net Profit Margin | 12.98% |
| Debt/Equity Ratio | 55.0% |
How did HOLX * perform over the long term?
See historical performance and comparison